Urolithin A — Safety, Research, Risks & Legal Status

Not medical advice. Urolithin A is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	UA, polyphenol metabolite, SIRT/mitophagy activator
Category	Supplement
gut_microbiota_dependent	True
polyphenol_metabolite	True
phase_2_trial_duration_weeks	4
variable_bioavailability	True
US legal status	Sold as a dietary supplement in the USA (DSHEA). Not FDA-approved. Produced from pomegranate and ellagic acid precursors. Available as standalone supplement or via pomegranate extract.

What is Urolithin A?

A polyphenolic metabolite produced by gut bacteria from ellagic acid (found in pomegranates, berries, nuts). Proposed to activate sirtuins and mitophagy (cellular cleanup of damaged mitochondria). Emerging compound with limited clinical development.

How it works

Urolithin A is produced from ellagic acid via gut bacterial metabolism (variable between individuals). Proposed to activate sirtuins and SIRT1-mediated mitophagy pathways, removing damaged mitochondria. Also proposed to activate AMPK and reduce oxidative stress.

Background & history

Urolithin A identified as pomegranate metabolite ~2000s. Amazentis founded to develop as clinical candidate. Phase 2 trial (4 weeks) in older adults published ~2021. Still early-stage; one company-sponsored trial only.

What the research says

Preclinical studies (rodents, cell culture) show improvements in mitophagy markers and mitochondrial function. One Phase 2 human trial (Amazentis) showed improved muscle strength and endurance markers in older adults over 4 weeks. Evidence is preliminary; limited human data.

Reported effects

Preclinical evidence for mitophagy activation and mitochondrial clearance
Small human trial suggests improved muscle strength and endurance markers
Studied for anti-inflammatory and antioxidant effects
Animal models suggest longevity and metabolic benefits (human translation unclear)
Potential improved mitochondrial quality control
Possible senolytic effects (removing aged cells) in preclinical models

Dosing & administration (informational)

Phase 2 trial used 500 mg daily. No established optimal dose; pomegranate ellagic acid content variable. Standalone urolithin A supplement doses typically 250-500 mg.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Limited human safety data; one trial showed good tolerability at study doses
Potential GI side effects from high-dose polyphenol intake
Long-term safety not established; human evidence is weeks only
Purity and bioavailability of standalone supplement formulations unclear
Endogenous production from diet (pomegranate) considered safe; synthetic isolated form less studied
Potential interaction with gut microbiota and uric acid metabolism

Drug & supplement interactions

Gut antibiotics: may reduce endogenous urolithin A production from pomegranate
Sirtuin activators (resveratrol, NMN): potential additive or unknown effects
AMPK activators (metformin): possible synergistic metabolic effects
Polyphenol-rich foods (berries, wine): additive antioxidant effects
Uric acid-lowering drugs (allopurinol): urolithin A increases serum urate (caution in gout)

Who should avoid it

Gout or hyperuricemia (urolithin A increases uric acid)
Severe GI disease or malabsorption syndrome
Pregnancy or lactation (insufficient safety data)
Gut dysbiosis (variable metabolism of ellagic acid)
Kidney disease with uric acid management concerns

How it is commonly combined

Urolithin A may stack with other mitophagy activators (spermidine, rapamycin) or NAD+ precursors (NMN, NR) but efficacy of combinations untested in humans; caution with multiple polyphenols.

Legal & regulatory. Sold as a dietary supplement in the USA (DSHEA). Not FDA-approved. Produced from pomegranate and ellagic acid precursors. Available as standalone supplement or via pomegranate extract.

Quality & harm reduction

T
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
i
m
p
o
r
t
a
n
t
;
v
e
r
i
f
y
c
o
n
t
e
n
t
o
f
u
r
o
l
i
t
h
i
n
A
(
n
o
t
j
u
s
t
e
l
l
a
g
i
c
a
c
i
d
p
r
e
c
u
r
s
o
r
)
.
B
i
o
a
v
a
i
l
a
b
i
l
i
t
y
p
o
o
r
u
n
l
e
s
s
f
o
r
m
u
l
a
t
e
d
f
o
r
a
b
s
o
r
p
t
i
o
n
;
m
a
n
y
p
r
o
d
u
c
t
s
l
a
c
k
t
e
c
h
n
o
l
o
g
y
.
P
o
m
e
g
r
a
n
a
t
e
e
x
t
r
a
c
t
i
s
d
i
e
t
a
r
y
s
o
u
r
c
e
;
p
u
r
i
f
i
e
d
u
r
o
l
i
t
h
i
n
A
i
s
r
e
s
e
a
r
c
h
-
g
r
a
d
e
a
n
d
e
x
p
e
n
s
i
v
e
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is urolithin A the same as pomegranate?

Urolithin A is produced by gut bacteria from ellagic acid in pomegranates. Eating pomegranate does not guarantee urolithin A production (depends on gut microbiota). Standalone urolithin A supplements are purified forms.

Does urolithin A actually improve strength?

One 4-week human trial reported improved muscle-strength markers. Evidence is minimal; larger longer trials needed before efficacy is established.

Can I get urolithin A from food?

Pomegranate and other ellagic-acid-rich foods (berries, walnuts) are dietary sources. Conversion to urolithin A depends on individual gut microbiota; production is variable.

Does urolithin A affect uric acid?

Urolithin A increases serum uric acid levels. Not recommended for patients with gout, hyperuricemia, or kidney disease with urate concerns.

References & further reading

Amazentis Phase 2 clinical trial publication
Preclinical mitophagy and sirtuins research in aging literature
Polyphenol and gut microbiota metabolism reviews
Pomegranate ellagic acid and urolithin A biochemistry studies